Clement Atlee W, M Vasudevan
This study was a placebo controlled, single centre prospective study to evaluate and compare the hypolipidemic activity of monotherapies of simvastatin (20 mg),ezetimibe(10 mg) and omega-3 fatty acids(4 g) over placebo treatment. Human dyslipidemic male subjects who had been selected based on the inclusionand exclusion criteria ,were divided into four groups of 21,20,22 and 20 subjects. The serum lipid profile level of these subjects were determined before and after 90 days treatments of placebo and above monotherapies. After 90 days of treatment, LDL cholesterol and total cholesterol levels were reduced significantly in simvastatin and ezetimibe groups while triglycerides level was significantly reduced and HDL cholesterol level increased in omega-3 fatty acids group compared to placebo group.